美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果分析
|
摘要
目的探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法选取2015年1月～2018年1月我院收治的60例冠心病心力衰竭患者,按照随机抽签方式将其分为对照组和观察组,每组各30例。对照组患者给予常规治疗,观察组给予美托洛尔联合曲美他嗪治疗,观察两组患者的临床总有效率、治疗前后左心室舒张末期内径(LVEDD)、左室射血分数(LVEF)、左心室收缩末期内径(LVESD)指标。结果观察组的临床总有效率(93.33%)明显高于对照组(70.00%),差异有统计学意义(P<0.05)。两组患者治疗前的LVEDD、LVEF、LVESD指标比较,差异无统计学意义(P>0.05)。观察组治疗后的LVEF明显高于治疗前及对照组,LVEDD、LVESD指标明显低于对照组及治疗前,差异有统计学意义(P<0.05)。结论采取美托洛尔联合曲美他嗪治疗冠心病心力衰竭,能有效改善患者心脏功能,临床疗效理想。
Objective To investigate the clinical effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease. Methods A total of 60 patients with heart failure of coronary heart disease admitted to our hospital from January 2015 to January 2018 were selected and divided into the control group and the observation group according to random lottery, 30 cases in each group. Patients in the control group were given routine treatment, while patients in the observation group were given Metoprolol combined with Trimetazidine. The clinical efficacy, left ventricular end-diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF) and left ventricular end systolic diameter(LVESD) were measured and observed before and after treatment in the two groups. Results The clinical total effective rate in the observation group was 93.33%, which was significantly higher than that in the control group(70.00%), and the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in LVEDD, LVEF and LVESD between the two groups(P>0.05). After treatment, the level of LVEF of the observation group was significantly higher than that before treatment and the control group, while the level of LVEDD and LVESD of the observation group were significantly lower than those before treatment and the control group, and the difference was statistically significant(P<0.05). Conclusion Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease can effectively improve the patient′s heart function, the clinical effect is ideal.
Objective To investigate the clinical effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease. Methods A total of 60 patients with heart failure of coronary heart disease admitted to our hospital from January 2015 to January 2018 were selected and divided into the control group and the observation group according to random lottery, 30 cases in each group. Patients in the control group were given routine treatment, while patients in the observation group were given Metoprolol combined with Trimetazidine. The clinical efficacy, left ventricular end-diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF) and left ventricular end systolic diameter(LVESD) were measured and observed before and after treatment in the two groups. Results The clinical total effective rate in the observation group was 93.33%, which was significantly higher than that in the control group(70.00%), and the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in LVEDD, LVEF and LVESD between the two groups(P>0.05). After treatment, the level of LVEF of the observation group was significantly higher than that before treatment and the control group, while the level of LVEDD and LVESD of the observation group were significantly lower than those before treatment and the control group, and the difference was statistically significant(P<0.05). Conclusion Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease can effectively improve the patient′s heart function, the clinical effect is ideal.
引文
[1]孙小军,卢京.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效观察[J].中国医院用药评价与分析,2015,15(3):312-314.
[2]李平,李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及疗效观察[J].海南医学院学报,2016,22(2):126-128.
[3]顾丽萍,胡菁,严蜀华,等.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志,2017,37(1):89-91.
[4]陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志,2018,46(6):667-670.
[5]施中平,戴海岳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国生化药物杂志,2017,37(9):278-279.
[6]姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[7]刘廷怡,刘瑶,王安伟,等.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志,2018,36(6):713-716.
[8]姚朝阳.麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2016,14(6):615-617.
[9]杨会萍,任骞.美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎性反应、T细胞亚群及心功能的影响研究[J].实用心脑肺血管病杂志,2016,24(8):20-23.
[10]强永在,高喜源.美托洛尔联合曲美他嗪治疗冠心病伴心力衰竭50例效果观察[J].内蒙古医科大学学报,2018,40(4):415-416,422.
[11]黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志,2016,14(21):2540-2541.
[12]王学影.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果[J].中国医药导报,2017,14(2):131-134.
[13]廖伟明,李海贞.曲美他嗪联合美托洛尔治疗冠心病心力衰竭的临床疗效[J].实用心脑肺血管病杂志,2018,26(Z1):56-57.
[14]王盟,张秀芹.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的效果分析[J].中国医学前沿杂志(电子版),2017,9(11):134-137.
[15]丁永广.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效及其对患者心功能及炎性反应的影响[J].实用心脑肺血管病杂志,2018,26(Z1):216-217.
[2]李平,李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及疗效观察[J].海南医学院学报,2016,22(2):126-128.
[3]顾丽萍,胡菁,严蜀华,等.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志,2017,37(1):89-91.
[4]陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志,2018,46(6):667-670.
[5]施中平,戴海岳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国生化药物杂志,2017,37(9):278-279.
[6]姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[7]刘廷怡,刘瑶,王安伟,等.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志,2018,36(6):713-716.
[8]姚朝阳.麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2016,14(6):615-617.
[9]杨会萍,任骞.美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎性反应、T细胞亚群及心功能的影响研究[J].实用心脑肺血管病杂志,2016,24(8):20-23.
[10]强永在,高喜源.美托洛尔联合曲美他嗪治疗冠心病伴心力衰竭50例效果观察[J].内蒙古医科大学学报,2018,40(4):415-416,422.
[11]黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志,2016,14(21):2540-2541.
[12]王学影.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果[J].中国医药导报,2017,14(2):131-134.
[13]廖伟明,李海贞.曲美他嗪联合美托洛尔治疗冠心病心力衰竭的临床疗效[J].实用心脑肺血管病杂志,2018,26(Z1):56-57.
[14]王盟,张秀芹.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的效果分析[J].中国医学前沿杂志(电子版),2017,9(11):134-137.
[15]丁永广.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效及其对患者心功能及炎性反应的影响[J].实用心脑肺血管病杂志,2018,26(Z1):216-217.